Riferimento farmaci
Dapagliflozin-saxagliptin
Dapagliflozin-saxagliptin is a medicine in the class gastrointestinal tract. It is used for diabetes mellitus.
- Classe del farmaco: Gastrointestinal Tract
- Indicato per: diabetes mellitus
Ultimo aggiornamento
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Gastrointestinal Tract
- Codice ATC
- A10BD21
- Forme farmaceutiche comuni
- compressa
- Dosaggi comuni
- 5 mg
- Nomi commerciali
- 3
- Paesi e mercati
- 3
Per cosa si usa
Come agisce
Dapagliflozin: Selective sodium-glucose transporter-2 (SGLT2) inhibitor; SGLT-2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion
Dose abituale nell'adulto (sintesi del foglio illustrativo)
Type 2 Diabetes Mellitus: 1 tablet (ie, 10mg/5mg) PO qDay in AM with or without food
Gravidanza e allattamento
- Gravidanza
- Unsafe Dapagliflozin: kidney changes in rat offspring; not recommended in the 2nd and 3rd trimesters. Saxagliptin: limited data, no harm in animals. Stop the combination when pregnancy is detected; insulin is preferred.
- Allattamento
- Unsafe No human milk data for either component; both pass into rat milk. Because of possible serious infant reactions (dapagliflozin and kidney maturation), the US label advises not to breastfeed.
Effetti indesiderati segnalati
- Diarrhea
- Back Pain
- Upper respiratory tract infection (URI)
- Urinary tract infections
- Dyslipidemia
- Headaches
Controindicazioni
- History of hypersensitivity to dapagliflozin or saxagliptin, including anaphylaxis, angioedema, or exfoliative skin conditions
- Moderate-to-severe renal impairment (eGFR <45 mL/min/1.73 m²), end-stage renal disease, or patients on dialysis
Chi deve prestare attenzione
- Acute pancreatitis reported; after initiating drug, monitor for signs and symptoms of pancreatitis; if suspected, promptly discontinue dapagliflozin/saxagliptin and initiate appropriate management
- May increase risk for developing heart failure (HF) or exacerbation of existing HR; observe patients for signs and symptoms of HF
- Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization reported in patients receiving SGLT2 inhibitors, including dapagliflozin; treatment with SGLT2 inhibitors increases risk for urinary tract infections; evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Dapagliflozin-saxagliptin: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altri farmaci della stessa classe
Domande frequenti
What is Dapagliflozin-saxagliptin used for?
Dapagliflozin-saxagliptin is a medicine in the class gastrointestinal tract. It is used for Diabetes mellitus.
What side effects have been reported with Dapagliflozin-saxagliptin?
Diarrhea, Back Pain, Upper respiratory tract infection (URI), Urinary tract infections, Dyslipidemia, Headaches.
Can Dapagliflozin-saxagliptin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Dapagliflozin: kidney changes in rat offspring; not recommended in the 2nd and 3rd trimesters. Saxagliptin: limited data, no harm in animals. Stop the combination when pregnancy is detected; insulin is preferred. Breastfeeding: Unsafe. No human milk data for either component; both pass into rat milk. Because of possible serious infant reactions (dapagliflozin and kidney maturation), the US label advises not to breastfeed.
What does Dapagliflozin-saxagliptin interact with?
MediHelp does not list a checked interaction for Dapagliflozin-saxagliptin yet. Always tell your pharmacist about every medicine you take.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
